|
Real-time Estimate
Cboe BZX
14:50:58 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 5.765 USD | +0.09% |
|
+44.85% | -6.26% |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 550.9 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | -3.89% | - | - |
| Enterprise Value (EV) 1 | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 502 | 483.2 | 450.3 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | -7.65% | -3.74% | -6.81% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -3.68x | -4.41x | -4.78x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | 1.61x | 1.71x | 1.65x |
| PEG | - | -0x | -0x | 0.2x | -0x | 0.1x | 0.3x | 0.61x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.71x | 0.67x | 0.63x |
| EV / Revenue | 2.7x | 1.56x | 2.12x | 1.42x | 0.66x | 0.65x | 0.59x | 0.52x |
| EV / EBITDA | 25.9x | -50.5x | -253x | 29.3x | 14x | -9.13x | -13.5x | -26.9x |
| EV / EBIT | 205x | -32.3x | -62.5x | 54.4x | 36x | -6.76x | -8.28x | -14.9x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.567 | -1.307 | -1.205 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 777.9 | 820.5 | 870.9 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | -54.98 | -35.73 | -16.75 |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | -74.3 | -58.34 | -30.26 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -139.6 | -106.2 | -117.5 |
| Net Debt 1 | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | -48.99 | -67.76 | -100.7 |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 5.760 | 5.760 | 5.760 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 95,650 | - | - |
| Announcement Date | 2/24/22 | 2/28/23 | 2/27/24 | 2/24/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.68x | 0.62x | -8.8x | -.--% | 533M | |
| 32.87x | 4.04x | 15.95x | 2.51% | 177B | |
| 20.65x | 3.58x | 12.8x | 2.94% | 118B | |
| 23.94x | 4.68x | 16.3x | 1.17% | 118B | |
| 30.93x | 3x | 12.11x | 2.29% | 91.21B | |
| 18.56x | 0.21x | 13.41x | 0.7% | 64.59B | |
| 31.76x | 7.96x | 20.46x | 1.24% | 56.13B | |
| 39.75x | 3.66x | 12.44x | 1.98% | 54.59B | |
| 38.38x | 9.31x | 26.04x | -.--% | 43.6B | |
| 40.74x | 3.29x | 12.28x | 0.53% | 33.95B | |
| Average | 27.39x | 4.03x | 13.30x | 1.34% | 75.8B | |
| Weighted average by Cap. | 29.18x | 4.14x | 15.31x | 1.82% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
